Compare iShares MSCI United Kingdom (FTSE) (EWU) vs IDEXX Laboratories, Inc. (IDXX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI United Kingdom (FTSE) vs IDEXX Laboratories, Inc. — how do they compare? iShares MSCI United Kingdom (FTSE) trades at $48.32, while IDEXX Laboratories, Inc. trades at $569.65 (market cap $46.22B). The key difference: iShares MSCI United Kingdom (FTSE) is trading nearer its 52-week high, IDEXX Laboratories, Inc. nearer its low. Which is the better fit depends on your goals.
| EWU | IDXX | |
|---|---|---|
Sector | Broad Market / Factor | Health |
52-Week High | $48.68 | $766.68 |
52-Week Low | $40.90 | $526.44 |
Market Cap | — | $46.22B |
Enterprise Value | — | $47.12B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EWU, the iShares MSCI United Kingdom ETF, trades at $48.37, down 0.25% on the day, with a bullish technical outlook supported by moving averages and strong trend indicators like ADX. Recent institutional activity includes Balefire LLC acquiring shares and Bank of America reducing its stake. The ETF is influenced by FTSE 100 performance, oil price volatility, and UK political developments under new Prime Minister Andy Burnham.
The outlook for EWU is cautiously optimistic, driven by bullish technical signals and exposure to UK equities, but risks from Middle East tensions, oil price swings, and political uncertainty may curb gains. Investors should weigh the ETF's diversification benefits against macroeconomic headwinds affecting British markets.
IDEXX Laboratories (IDXX) trades at $570.58, down 4.23% over 24 hours, with a bullish technical signal and strong fundamentals. The stock has consistently beaten earnings estimates, with Q2 2026 EPS of $4.27 surpassing the $3.94 expectation. Revenue growth remains robust, supported by a 74.21% ROE and expanding diagnostic offerings. Recent news highlights product expansion, including a dual-species cardiac test, reinforcing its market leadership in veterinary diagnostics.
The outlook is positive, driven by durable competitive advantages and international growth potential. However, elevated valuation multiples and competitive pressures pose risks. Analyst consensus is bullish with a $683.33 price target, suggesting significant upside from current levels, though investors should monitor execution on guidance and macroeconomic headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares MSCI United Kingdom (FTSE)
EWU is a country-specific ETF that tracks the performance of the United Kingdom equity market. It provides exposure to large and mid-sized UK companies, with significant weightings in financials, energy, and healthcare, including Shell, AstraZeneca, and HSBC.
Read more on EWU →About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →
